[Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].

Liang Y, Wei H, Zhang JL, Hou L, Luo XP

Zhonghua er ke za zhi = Chinese journal of pediatrics1 Nov 2004Cited by 2 (Europe PMC)

PMID15631714PepBankPUB-15631714

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

01HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, both triptorelin regimens completely suppressed the pituitary-gonadal axis.
In plain wordsIn girls with early puberty, both triptorelin regimens completely suppressed the pituitary-gonadal axis.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePituitary-gonadal axis suppression
Study
n = 46
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
Both treatment regimes can completely suppressed the pituitary-gonadal axis.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171401
02HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, clinical pubertal signs regressed or stabilized during triptorelin treatment.
In plain wordsIn girls with early puberty, clinical pubertal signs regressed or stabilized during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
MixedClinical pubertal development
Study
n = 46
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The clinical signs of pubertal development regressed or stabilized in all patients.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171402
03HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, breast development regressed during triptorelin treatment.
In plain wordsIn girls with early puberty, breast development regressed during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBreast development
Study
n = 46
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
Breast developments, as reflected by Tanner staging, were regressed.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171403
04HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, uterine volume decreased nonsignificantly after triptorelin treatment.
In plain wordsIn girls with early puberty, uterine volume decreased without statistical significance after triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeUterine volume
Study
n = 46
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
Uterine volume decreased after treatment, however, this decrease did not reach statistical significance.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171404
05HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, ovarian volume did not change significantly during triptorelin treatment.
In plain wordsIn girls with early puberty, ovarian volume did not change significantly during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOvarian volume
Study
n = 46
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
Mean ovarian volume did not change significantly during treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171405
06HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, skeletal maturation slowed significantly during triptorelin treatment.
In plain wordsIn girls with early puberty, skeletal maturation slowed significantly during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSkeletal maturation rate
Study
n = 46
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The rate of skeletal maturation was reduced significantly during treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171408
07HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, predicted adult height increased significantly and progressively during triptorelin treatment.
In plain wordsIn girls with early puberty, predicted adult height increased significantly and progressively during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePredicted adult height
Study
n = 46
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The predicted adult height increased significantly and progressively during therapy.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171411
08HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, LH returned to prepubertal levels and remained suppressed during triptorelin treatment.
In plain wordsIn girls with early puberty, LH returned to prepubertal levels and remained suppressed during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum LH
Study
n = 46
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The levels of serum LH, FSH and E(2) were returned to the prepubertal condition after 6 - 8 weeks treatment and remained suppressed for the duration of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171412
09HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, FSH returned to prepubertal levels and remained suppressed during triptorelin treatment.
In plain wordsIn girls with early puberty, FSH returned to prepubertal levels and remained suppressed during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum FSH
Study
n = 46
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The levels of serum LH, FSH and E(2) were returned to the prepubertal condition after 6 - 8 weeks treatment and remained suppressed for the duration of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171413
10HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, estradiol returned to prepubertal levels and remained suppressed during triptorelin treatment.
In plain wordsIn girls with early puberty, estradiol returned to prepubertal levels and remained suppressed during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum estradiol
Study
n = 46
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The levels of serum LH, FSH and E(2) were returned to the prepubertal condition after 6 - 8 weeks treatment and remained suppressed for the duration of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171414
11HumanRandomized controlled trialSafety outcome
In girls with idiopathic central precocious puberty, no significant side effects were reported during triptorelin treatment.
In plain wordsIn girls with early puberty, no significant side effects were reported during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSignificant side effects
Study
n = 46
Outcome group
Adverse events · Whole body
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Source sentences
Summary
No significantly side effects of therapy were noted.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171415
12HumanRandomized controlled trialSafety outcome
In girls with idiopathic central precocious puberty, two girls had minimal withdrawal bleeding after the first triptorelin injection.
In plain wordsIn girls with early puberty, two girls had minimal withdrawal bleeding after the first triptorelin injection.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableWithdrawal vaginal bleeding
Study
n = 46
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
3.75 mg · subcutaneous or intramuscular · More than 12 monthsAs given in this study (human).
Measurements
Girls with withdrawal bleeding
2 girls
after first injection
Source sentences
Summary
Two girls had minimal withdrawal virginal bleeding episodes after the first injection.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171417
13HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, subcutaneous triptorelin significantly reduced height velocity from pretreatment values.
In plain wordsIn girls with early puberty, subcutaneous triptorelin significantly reduced growth speed from pretreatment values.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseHeight velocity with subcutaneous regimen
Study
n = 26
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · subcutaneous · More than 12 monthsAs given in this study (human).
Measurements
Height velocity before treatment
6.3 cm/year
group A
Height velocity during treatment
5.8 cm/year
group A
Source sentences
Summary
The height velocity was significantly decreased from a pretreatment value of 6.3 +/- 1.4 cm/year to 5.8 +/- 1.2 cm/year in group A and 6.7 +/- 1.3 cm/year to 5.4 +/- 1.0 cm/year in group B, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171406
14HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, the bone age to chronological age ratio decreased with subcutaneous triptorelin.
In plain wordsIn girls with early puberty, the bone age to chronological age ratio decreased with subcutaneous triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone age to chronological age ratio with subcutaneous regimen
Study
n = 26
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg · subcutaneous · More than 12 monthsAs given in this study (human).
Measurements
Initial bone age/chronological age
1.2 ratio
group A
Final bone age/chronological age
0.7 ratio
group A
Source sentences
Summary
The ratio of bone age/chronological age was 1.2 +/- 0.2 or 1.3 +/- 0.3 at the onset of therapy and decreased significantly after the treatment to 0.7 +/- 0.2 or 0.9 +/- 0.1, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171409
15HumanRandomized controlled trialSafety outcome
In girls receiving subcutaneous triptorelin, a non-irritating injection-site mass was the most common adverse event and disappeared after 8 - 12 weeks.
In plain wordsIn girls receiving subcutaneous triptorelin, a non-irritating injection-site mass was the most common adverse event and later disappeared.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSubcutaneous injection-site mass
Study
n = 26
Outcome group
Adverse events · Skin and wound
Studied dose
3.75 mg · subcutaneous · More than 12 monthsAs given in this study (human).
Measurements
Time to disappearance of injection-site mass
8 to 12 weeks
group A (subcutaneous)
Source sentences
Summary
The most common adverse event during SC treatment was that a non-irritating, 1 cm in diameter mass can be palpated at the site of subcutaneous injection in the abdominal wall of group A patients.
4 context sentences(design, population, supporting numbers)
Summary · context
It gradually decreased in size, and disappeared after 8 - 12 weeks.
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171416
16HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, intramuscular triptorelin significantly reduced height velocity from pretreatment values.
In plain wordsIn girls with early puberty, intramuscular triptorelin significantly reduced growth speed from pretreatment values.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseHeight velocity with intramuscular regimen
Study
n = 20
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · intramuscular · More than 12 monthsAs given in this study (human).
Measurements
Height velocity before treatment
6.7 cm/year
group B
Height velocity during treatment
5.4 cm/year
group B
Source sentences
Summary
The height velocity was significantly decreased from a pretreatment value of 6.3 +/- 1.4 cm/year to 5.8 +/- 1.2 cm/year in group A and 6.7 +/- 1.3 cm/year to 5.4 +/- 1.0 cm/year in group B, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171407
17HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, the bone age to chronological age ratio decreased with intramuscular triptorelin.
In plain wordsIn girls with early puberty, the bone age to chronological age ratio decreased with intramuscular triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone age to chronological age ratio with intramuscular regimen
Study
n = 20
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg · intramuscular · More than 12 monthsAs given in this study (human).
Measurements
Initial bone age/chronological age
1.3 ratio
group B
Final bone age/chronological age
0.9 ratio
group B
Source sentences
Summary
The ratio of bone age/chronological age was 1.2 +/- 0.2 or 1.3 +/- 0.3 at the onset of therapy and decreased significantly after the treatment to 0.7 +/- 0.2 or 0.9 +/- 0.1, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Forty-six girls with ICPP were enrolled in this trial and were divided into two groups at random, with 26 patients in group A and 20 in group B.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6 weeks intervals in group A or intramuscularly (IM) at 4 weeks intervals in group B.
Summary · context
Both forms were given for more than 12 months consecutively.
Report a problemFND-1563171410

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.